Hikma Pharmaceuticals USA Inc. announced this morning that the FDA approved a supplemental ANDA for Methadone Hydrochloride Oral Solution, a generic form of the abused narcotic. This regulatory win bolsters the company’s established opioid portfolio and immediately strengthens its competitive stance in the generic pain and addiction treatment markets amid ongoing industry scrutiny.